---
schema_version: "secwatch.filing_event.v1"
accession: "0001802768-25-000113"
form_type: "8-K"
ticker: "RPRX"
cik: "0001802768"
company_name: "Royalty Pharma plc"
filed_at: "2025-11-05T23:59:59+00:00"
generated_at: "2026-05-17T00:22:28.968868+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Royalty Pharma Q3 Portfolio Receipts +11% to $814M; raises FY guidance to $3,200-$3,250M

## Summary
- Portfolio Receipts $814M (+11% YoY); Royalty Receipts $811M (+11%). Net cash ops $703M.
- Raised FY 2025 guidance: Portfolio Receipts now $3,200-$3,250M (14-16% growth, previously $3,050-$3,150M).
- Adjusted EBITDA $779M, Portfolio Cash Flow $657M. Capital Deployment $1.0B in Q3 (Imdelltra, obexelimab, Amvuttra).
- Repurchased 4M shares for $152M in Q3; $1.2B YTD share repurchases.
- Issued $2B senior notes at 5.16% in Sep; repaid $1B notes in Aug; total debt $9.2B at 3.75% avg cost.

## SEC filing metadata
- accession: 0001802768-25-000113
- form_type: 8-K
- ticker: RPRX
- cik: 0001802768
- company_name: Royalty Pharma plc
- filed_at: 2025-11-05T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1802768/000180276825000113/0001802768-25-000113-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1802768/000180276825000113/rprx-20251105.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001802768-25-000113
- JSON: https://secwatch.observer/filing/0001802768-25-000113.json
- Plain text: https://secwatch.observer/filing/0001802768-25-000113.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.